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ABSTRACT  
 
Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that regulates 
the turnover of proteins in a cell. To date several interacting partners that are involved in 
various cellular processes have been identified for USP7. Many of the interacting 
partners of USP7 contain a P/AxxS motif. We have identified two E2 ubiquitin-
conjugating enzymes, UbE2E2 and UbE2E3, which contain the P/AxxS motif. Using a 
co-immunoprecipitation assay we have shown that these E2 proteins interact with USP7 
through their P/AxxS motif. Co-crystal structures of the N-terminal domain of USP7 
(USP7-NTD) and the E2 peptides reveal that the interactions are formed between USP7-
NTD residues 164DWGF167 and the E2 P/AxxS motifs. It has also been established that 
USP7 may be involved in regulating the cellular levels of UbE2E2. Overall, our findings 
suggest USP7, a de-ubiquitinating enzyme, is a regulator of ubiquitin-conjugating 
enzymes, which are involved in the ubiquitination cascade.  
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CHAPTER 1: INTRODUCTION  
1.1 Ubiquitin 
 Ubiquitin is an 8.5 kDa protein that is highly conserved amongst eukaryotes 
(Goldstein et al., 1975).  The critical elements of its sequence include a di-glycine motif 
at the C-terminal end and seven lysine residues occurring at positions 6, 11, 27, 29, 33, 
48 and 63 (Figure 1.1).  Ubiquitin is expressed as either a polyubiquitin chain or as a 
fusion protein with an essential ribosomal polypeptide (Kimura and Tanaka, 2009). In 
mammals ubiquitin is encoded by 4 genes; Ubb, Ubc, Uba52 and Uba80, two of which 
encode the polyubiquitin and two of which encode the ribosomal fusion ubiquitin. 
Although ubiquitin is abundant in all eukaryotic cells, it is highly regulated by ubiquitin 
encoding genes, by a change in proteasome composition and by de-ubiquitinating 
enzymes (Kimura and Tanaka, 2009).  
In a process called ubiquitination, ubiquitin is conjugated to a lysine residue on a 
substrate protein at a single site or as a polymer formed by the polymerization of 
ubiquitin monomers (Pickart, 2001). Ubiquitination can induce cellular processes such as 
protein degradation, endocytosis, DNA repair, chromatin remodeling and initiation of 
inflammatory response (Pickart, 2001). The type of cellular process induced depends on 
the amount of ubiquitin molecules attached to the protein and the topology of the 
ubiquitin chain, which depends on the lysine residue used for attachment. For example, a 
ubiquitin chain linked by K48 will target the modified protein for degradation by the 26S 
proteasome (Peng et al., 2003). 
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Figure 1.1: Ubiquitin is a 76 amino acid polypeptide. Ubiquitin is attached to a protein 
substrate in a process called ubiquitination. The crucial elements of its structure are a di-
glycine motif at the C-terminal end (point of attachment) and seven lysine residues 
located at positions 6, 11, 27, 29, 33, 48 and 63. The figure was retrieved and modified 
from Komander (2009).  
 
1.2 Ubiquitination  
Ubiquitination is a post-translational modification in which a ubiquitin molecule 
is added to a substrate protein. Ubiquitination is a three-step process that involves the 
cooperative action of three enzymes; ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin ligase (E3) (Figure 1.2). First, E1 catalyzes the 
acyl-adenylation of the C-terminus of ubiquitin, forming an ubiquitin-adenylate 
intermediate that is ready for nucleophillic attack. The ubiquitin-adenylate intermediate is 
then transferred to the cysteine residue in the E1 active site creating a thioester bond 
between the carboxyl group of G76 in ubiquitin and the sulfhydryl group of the catalytic 
cysteine of E1. The activated thiol- linked ubiquitin is transferred to the catalytic 
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cysteine of E2 (Pickart, 2001). E2-ubiquitin interacts with E3, which recognizes a 
specific protein substrate and mediates the transfer of the activated ubiquitin molecule on 
E2 to the protein substrate (Passmore and Barford, 2004). The way in which the ubiquitin 
molecule is transferred from the E2 to the substrate protein depends on the presence of 
either a HECT domain or a RING finger in the E3. When a HECT domain is present in 
the E3, the ubiquitin molecule is transferred from the E2 to the active site cysteine of the 
E3. The ubiquitin molecule is then transferred from the E3 to the substrate protein 
(Passmore and Barford, 2004). On the other hand, RING finger E3s act as a scaffold, 
facilitating the transfer of ubiquitin from the E2 to the substrate protein (Passmore and 
Barford, 2004). The protein substrate and the ubiquitin molecule are attached by an 
isopeptide bond that is formed between the carboxyl group of G76 on ubiquitin and the 
$-amino of a lysine in the substrate protein (Pickart, 2001). The process of ubiquitination 
can terminate forming a monoubiquitinated protein or it can continue forming an 
ubiquitin polymer, in which the G76 of the incoming ubiquitin is attached to one of seven 
lysine residues on the attached ubiquitin (Figure 1.2).  
In humans there are six different E1s, approximately 35 different E2s and over 
one thousand E3s (van Wiljk and Timmers, 2010).  Compared to E3s, E2s are comprised 
of a much smaller number of enzymes and there remains a gap in the knowledge about 
their function and the molecular mechanisms involved in their regulation.  
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Figure 1.2: Ubiquitination involves the cooperation of three enzymes. Ubiquitination 
is a post-translational modification that is facilitated by the cooperative action of three 
enzymes; ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligase (E3). The fate of the substrate protein depends on the amount and 
topology of ubiquitin molecules attached. Ubiquitination is reversible.  The reversal of 
ubiquitination is catalyzed by deubiquitinating enzymes (DUBs). This image was 
retrieved from Hamilton and Zito, 2013. 
1.3 Ubiquitin-Conjugating Enzymes (E2s) 
1.3.1 Function of E2s 
 E2s are the second enzyme in the ubiquitination cascade. E2s bind an 
E1-activated ubiquitin via their catalytic cysteine residue. The E2-ubiquitin conjugate 
then selectively interacts with a specific E3 ligase, which recruits a protein substrate to be 
ubiquitinated. E2 enzymes play a role in determining which of the seven-lysine residues 
in ubiquitin are used in polyubiquitination, thereby influencing the fate of the substrate 
protein (David et al., 2010).  Different E2 enzymes have a different preference for which   
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lysine residue is used for polyubiquitination; the most commonly used lysine residues are 
lysine 11, 48 and 63 (David et al., 2010). It has been shown that polyubiquitin chains are 
formed at the active site cysteine in the E2 enzyme and are transferred from the E2 to the 
substrate protein (Li et al., 2007; David et al., 2010). If a substrate protein is tethered to 
an E2 enzyme, the E2 enzyme could ubiquitinate the substrate in absence of an E3 ligase. 
However, the type of ubiquitin conjugate and the identity of the target lysine residue on 
the substrate protein are not specific (David et al., 2011).  
 
 1.3.2 Localization of E2s 
 Most E2s are expressed in a variety of cell types and tissues; however, some are 
predominantly expressed in specific tissues. For example, UbE2K is highly expressed in 
certain regions of the brain (van Wiljk and Timmers, 2010). Inside the cell, E2s are 
present in both the nucleus and the cytoplasm. When tagged with a ubiquitin, certain E2s 
can be transported from the cytoplasm to the nucleus by the transport receptor 
importin-11 (Plafker et al., 2004).  
 
 1.3.3 Structure of E2s 
E2s have an evolutionarily conserved, ~150-200 amino acid ubiquitin-conjugating 
catalytic fold (UBC) (Burroughs et al., 2008).  The UBC fold consists of a four-stranded 
antiparallel !-sheet that is flanked by one %-helix at the N-terminal end (helix 1) and two 
%-helices at the C-terminal end (helices 2a and 2b) (Burroughs et al., 2008; Wenzel et al.,   
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2011; Figure 1.3A).  Loop 1 and loop 2, which connect !-strand 1 and 2 and !-strand 3 
and 4, respectively, have a lot of sequence variability amongst E2s and are thought to be 
involved in selectively binding E3s (van Wiljk and Timmers, 2010). The active site 
cysteine is positioned in the highly conserved loop region connecting helix 2 with 
!-strand 4 (Burroughs et al., 2008; van Wiljk and Timmers, 2010). Within ten residues 
upstream of the active site cysteine lays a highly conserved HxN sequence. It is thought 
that the histidine maintains the structure of the active site and the asparagine is involved 
in catalysis of the isopeptide bond formed between the ubiquitin in the active site and the 
substrate protein (Wenzel et al., 2011).  
E2s are classified into four families based on their structural organization.  Class I 
E2s consist only of a UBC fold; class II E2s have a UBC fold and a C-terminal extension; 
class III E2s have a UBC fold and a N-terminal extension; and class IV E2s have a UBC 
fold and both a C- and N-terminal extension. Unlike the UBC fold, which is 95% 
conserved amongst all E2 families, the extensions are not conserved. These extensions 
account for functional differences amongst E2s, as well as differences in subcellular 
localization (van Wiljk and Timmers, 2010). 
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Figure 1.3: E2s have a conserved UBC fold and are divided into four classes based 
on their structure. (A) The UBC fold has 3 %-helices; one at the N-terminus (helix 1) 
and two at the C-terminus (helix 2a and 2b). The %-helices surround an antiparallel, 
4-stranded !-sheet and a C-terminal flap that contains two extended elements. The 
catalytic cysteine is located in an exposed region of the flap (yellow). The conserved 
histidine and asparagine elements are located in the N-terminal region of the flap 
(yellow). All other conserved residues are depicted in stick form. This figure was 
retrieved and altered from Burroughs et al. (2009). (B) E2s are divided into 4 classes 
based on their structure. Class I E2s have only a UBC fold; class II E2s have a C-terminal 
extension; Class III E2s have an N-terminal extension; and class IV E2s have both a C 
and N-terminal extension. This figure was retrieved and altered from van Wiljk and 
Timmers, (2010).   
!-SHEET  
A
B
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1.4 Class III Ubiquitin-Conjugating Enzymes  
The human genome encodes nine class III ubiquitin-conjugating enzymes 
(class III E2s) (van Wiljk and Timmers, 2010). Class III E2s are characterized by the 
presence of an N-terminal extension. The UBC fold of the class III E2s is 94% conserved 
amongst eukaryotes and is composed of approximately 149 amino acid residues 
(Matuschewski et al., 1996). In contrast to the UBC fold, the N-terminal extensions of the 
class III E2s bear little sequence similarity and differ in size (Matuschewski et al., 1996). 
The minimal sequence similarity between the N-terminal extensions comes from clusters 
of serine and threonine residues (Matuschewski et al., 1996).   
The class III E2s UbE2E1, UbE2E2 and UbE2E3 have 97% sequence similarity 
over the 143 amino acid residues in their UBC domain. The high sequence similarity 
between their UBC domains gives these three enzymes overlapping properties. First, a 
ubiquitin-charged form of these enzymes can be transported to the nucleus via the 
importin-11 transport receptor (Plafker et al., 2004).  Second, these enzymes share 
common E3-ligase binding partners such as ARA54, RNF8 and cullin-3 E3 ligases (Ito et 
al. 2001; Plafker et al. 2009). In contrast to their UBC domain, their N-terminal 
extensions vary in length and have little sequence similarity (Figure 1.4). 
Schumacher et al. (2013) have recently shown that the N-terminal extension of the 
UbE2E enzymes limits ubiquitin transfer. In an experiment with the UBC fold alone, the 
UbE2E enzymes were able to polyubiquitinate a substrate. However, the full-length 
protein was only able to monoubiquitinate the same substrate (Schumacher et al., 2013).  
Although the N-terminal extension limits the ubiquitin transfer potential of all three 
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UbE2E enzymes, the lack of sequence similarity in these extensions is the factor 
determining the substrate specificity and unique function of these enzymes. 
 
 
Figure 1.4: The N-terminal extensions of the UbE2E proteins bear little sequence 
similarity. A sequence alignment of the N-terminal extensions of the UbE2E proteins 
shows little sequence similarity. Residues highlighted in yellow are conserved amongst 
the three proteins. The USP7 substrate recognition motif, PSTS is also conserved 
amongst the three proteins.  
 
 
1.4.1 UBE2E1 
 UbE2E1 is a 21.4 kDa protein with a N-terminal extension that is 49 amino acid 
residues in length. UbE2E1 has been implicated in histone ubiquitination. It has been 
shown that UbE2E1 interacts with RNF20/40, an E3 ligase, and the hPAF complex to 
monoubiquitinate lysine 120 in Histone 2B (H2B).  The mono-ubiquitination promotes 
expression of HOX genes (Zhu et al., 2005).  
 
1.4.2 UbE2E2 
UbE2E2 is a 22.3 kDa protein with a N-terminal extension that is 58 amino acid 
residues in length. Aside from acting as a ubiquitin-conjugating enzyme, not much is 
known about the function of UbE2E2. However, a recent genetic association study has 
implicated UbE2E2 in gestational diabetes mellitus (GDM). The study showed that one 
(49nt)!!"#$#%&'()*+,&
!"#$#$&'-.*+,&
!"#$#/&'0(*+,&
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of two single-nucleotide polymorphisms for UbE2E2 showed a significant association 
with GDM in a recessive model (Kim et al., 2013).  
 
1.4.3 UbE2E3 
UbE2E3 is a 22.9 kDa protein with a N-terminal extension that is 64 amino acid 
residues in length.  In the past decade, much has been uncovered about the function of 
UbE2E3. Plafker et al. (2008) implicated UbE2E3 as an essential enzyme involved in the 
proliferation of retinal pigment epithelial (RPE) cells. Furthermore, UbE2E3 was 
implicated in restoring redox homeostasis after oxidative stress (Plafker et al., 2010). 
Although there is some insight regarding the function of the class III E2 enzymes, not 
much is known about their regulation.  
1.5 De-Ubiquitinating Enzymes (DUBs) 
  Ubiquitination is a reversible process. Reversibility of ubiquitination is facilitated 
by a group of enzymes known as de-ubiquitinating enzymes (DUBs). DUBs remove 
ubiquitin or ubiquitin-like proteins from pro-proteins and conjugates by hydrolyzing the, 
thioester and amide bonds at G76 of ubiquitin.  
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1.5.1 The Role of DUBs in the Cell  
 DUBs play several roles in the cell. First, they process primary ubiquitin gene 
products (Reyes-Turcu, 2009). Ubiquitin is expressed either in the form of a 
polyubiquitin chain or fused to one of the two ribosomal proteins. In order for ubiquitin 
to become a mature protein, it must be processed into a monomer. DUBs process the 
ubiquitin pro-protein to produce an active monomer (Reyes-Turcu, 2009). Second, DUBs 
reverse the ubiquitin or ubiquitin-like modification of target proteins by removing the 
ubiquitin or ubiquitin like moiety, therefore, salvaging the target protein from its eventual 
fate (Reyes-Turcu, 2009).  Third, DUBs are responsible for recycling of ubiquitin (Kim et 
al., 2003). Following degradation of the target protein by the 26S proteasome, DUBs 
disassemble polyubiquitin chains and remove protein remnants to produce ubiquitin 
monomers that are reused in the ubiquitination cascade (Kim et al., 2003). Finally, DUBs 
can edit the topology of the ubiquitin chain, thus preventing inappropriate ubiquitin 
signaling (Kim et al., 2003).  
 
1.5.2 Classification of DUBs  
 The Human Genome Project has identified almost 100 putative DUBs. These 
DUBs are classified into two families based on their mechanism of catalysis: cysteine 
proteases and metalloproteases. The cysteine protease family is further divided into four 
super families: ubiquitin C-terminal hydrolases (UCH), ubiquitin specific proteases 
(USP/UBP), the ovarian tumor domain (OTU) and Machado-Josephian domain (MJD)  
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(Reyes-Turcu, 2009). The metalloprotease family is comprised of one zinc-dependent 
superfamily JAB1/MPN/Mov34 (JAMM) (Reyes-Turcu, 2009). 
The largest superfamily of DUBs is the USP/UBP superfamily. DUBs in this 
superfamily have a highly conserved 350 amino acid core domain, which is comprised of 
three subdomains called finger, palm and thumb (Kim et al., 2003). The core domain has 
a variety of N-terminal and C-terminal extensions and insertions and contains a catalytic 
cysteine (Kim et al., 2003). The region surrounding the catalytic cysteine is homologous 
amongst the members of this superfamily and contains a Cys and His box (Kim et al., 
2003). One of the proteins studied in this project is a DUB belonging to the USP/UBP 
superfamily called Ubiquitin Specific Protease 7 (USP7).  
1.6 Ubiquitin Specific Protease 7 (USP7/HAUSP) 
 Ubiquitin-Specific Protease 7 (USP7) was first identified as a 135 kDa protein 
that binds to the Herpes Simplex Virus protein, ICP0 (Meredith et al., 1994). For this 
reason it was named Herpesvirus Associated Ubiquitin Specific Protease (HAUSP). 
USP7 is conserved throughout eukaryotic evolution and is expressed in a variety of cell 
types (Everett et al., 1997). 
 
1.6.1 Domains  
USP7 is an 1102 amino acid protein and is comprised of three domains; 
N-terminal domain (NTD), catalytic domain and C-terminal domain (CTD) (Figure 1.5). 
The catalytic domain spans residues 208-560 and is composed of three sub-domains: 
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finger, thumb and palm (Hu et al., 2002). Like other USP proteins, the catalytic domain 
of USP7 contains a conserved Cys and His box (Hu et al., 2002). The Cys box contains 
the catalytic cysteine, Cys223, which gets deprotonated and unleashes nucleophillic 
attack on the carbonyl carbon atom of Gly76 in ubiquitin (Hu et al., 2002). The 
deprotonation of the Cys223 is facilitated by an adjacent His464 residue, which is 
stabilized by a nearby Asn or Asp residue. Together these three residues comprise the 
catalytic triad and sit in a site called the catalytic cleft (Hu et al., 2002). Upon binding of 
ubiquitin the structure of the catalytic cleft changes to bring the Cys and His residues in 
closer proximity (Hu et al., 2002).  
A TRAF homology domain at the N-terminus and five ubiquitin-like (UBL) 
domains at the C-terminus surround the catalytic domain (Figure 1.5). The TRAF-like 
NTD spans residues 54-205 and forms an eight-stranded, anti parallel !-sandwich 
(Saridakis et al., 2005). The NTD has been implicated in substrate recognition and 
interaction (Saridakis et al., 2005, Sheng et al 2006). The five UBLs span residues 
560-1102 and together comprise the CTD (Faesen et al., 2011). Functional analysis of 
USP7 showed that the CTD is required for full activity of the enzyme. Specifically, 
UBL4 and UBL5 activate the catalytic domain and promote ubiquitin binding 
(Faesen et  al., 2012).  
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Figure 1.5: USP7 is an 1102 amino acid protein with 3 domains. (A) USP7 is a 
135 kDa protein that is comprised of 1102 amino acids and 3 domains. The N-terminal 
domain spans from amino acids 54-205 and is involved in substrate binding. The catalytic 
domain contains an active site cysteine and spans amino acids 208-560.  The C-terminal 
(CTD) domain is the largest and spans amino acids 560-1102. The CTD consists of 5 
ubiquitin-like domains (UBLs). Each UBL is structurally homologous to ubiquitin but 
lacks glycine 76.  (B) The crystal structures of the N-terminal domain (top left), catalytic 
domain (top right) and C-terminal domain (bottom) were determined by (Saridakis et al., 
2005), (Hu et al., 2002) and (Faesen et al., 2011), respectively.  
 
  
!"#$%&'()%*
+,-+./0.1*
-234235*
467023**
!"#$()8'%9)*
:0.0;<=:*467023*
!"#$%9)'>>)(*
,-2?,2=3';2@1*467023+*
>*****%&***********************()%******************************************************%9)***********************************************************************************>>)(*
!AB'>* !AB'(* !AB'C* !AB'&* !AB'%*
98&'$$)* $DC'88)* D89'>)8)*8D&'D$&*%9&'99&*
A
B
 15 
1.6.2 Cellular Function of USP7  
 USP7 has been implicated in several cellular processes such as tumour 
suppression, viral infection, immune response, DNA damage response and epigenetics.  
Perhaps it is best known for its dynamic role in the p53-Mdm2 tumor suppression 
pathway. Under regular cellular conditions, p53 levels are kept low by the E3 ubiquitin 
ligase Mdm2, which mediates the ubiquitylation and subsequent degradation of p53 
(Moll and Petrenko, 2003). Upon oncogenic stress, p53 levels are strongly stabilized via 
deubiquitination by USP7, allowing for p53-dependent cell growth repression and 
apoptosis (Li et al., 2002).  This demonstrates a tumour suppressor function for USP7. 
Interestingly, USP7 has also been implicated in stabilizing the p53 antagonist Mdm2 
suggesting that it is involved in a feedback loop that regulates p53 function (Li et al., 
2004).  
 In addition to its role as a tumor suppressor, USP7 has been shown to interact 
with viral proteins. One such protein is Epstein Barr Nuclear Antigen 1 (EBNA1), which 
interacts with the USP7-NTD (Holowaty et al., 2003).  EBNA1 competes with tumour 
suppressor p53 for USP7 binding (Saridakis et al., 2005). By binding to the USP7-NTD, 
EBNA1 prevents p53-dependent cell cycle arrest and apoptosis, allowing for cell 
immortalization by the Epstein Barr Virus (Saridakis et al., 2005). 
 While EBNA1 binds to the NTD of USP7, another viral protein called ICP0 
interacts with the CTD of USP7. ICP0 is a Herpes Simplex Virus (HSV) immediate early 
protein. Unlike EBNA1, which binds to USP7 to prevent it from performing its function  
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as a deubiquitinase, ICP0 binds USP7 to facilitate its export to the cytoplasm where it 
modulates Toll-like Receptor (TLR) mediated innate immune response (Daubeuf et al., 
2009). One way in which TLRs mediate innate immune response is through a signaling 
pathway that activates the transcription factor NF-#B, which in turn transcribes 
inflammatory cytokines (Kawai and Akira, 2007). TRAF6 and IKK" are two components 
of the TLR signaling pathway that lead to activation of NF-#B. TRAF6 is an E3 ligase 
that ubiquitinates itself and IKK". Ubiquitinated TRAF6 and IKK" eventually lead to the 
activation of NF-#B (Kawai and Akira, 2007). ICP0 recruits USP7 to the cytoplasm, 
where it binds and deubiquitinates TRAF6 and IKK", preventing NF-#B mediated 
inflammatory response (Daubeuf et al., 2009). Exploitation of USP7 by the viral protein 
ICP0 allows HSV to bypass innate immune response (Daubeuf et al., 2009).  
Moreover, USP7 has been implicated in epigenetic silencing. USP7 interacts with 
a metabolic enzyme called GMP synthase (GMPS). The interaction between USP7 and 
GMPS leads to deubiquitination of monoubiquitinated histone H2B (uH2B), which in 
turn leads to epigenetic silencing of homeotic genes in Drosophila (van der Knapp et al., 
2005).  
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1.6.3 Substrates and Interacting Motif of the USP7-NTD 
 USP7 interacts with the Epstein-Barr nuclear antigen 1 (EBNA1) through an 
444EGPS447 motif in the EBNA1 protein (Saridaks et al., 2005). The most essential 
residues involved in the interaction were Glu444 and Ser447 in EBNA1 and Asp164 and 
Trp165 in USP7. Further studies with the USP7-NTD revealed that a 359PGGS362 motif in 
p53 was essential for binding to the USP7-NTD (Sheng et al., 2006). Pro359 and S362 
were most critical to this interaction as mutation of either residue reduced the binding up 
to two-fold and a double mutant reduced binding three-fold (Sheng et al., 2006). 
Examination of the p53 protein sequence revealed another motif (364AHSS367) that is 
critical for the interaction with USP7-NTD. In this motif Ala364 mediates the same 
interactions with USP7-NTD as does Pro359 and Ser367 mediates the same contacts as 
Ser362 (Sheng et al., 2006). Similar binding motifs were found in Mdm2 (156PSTS159, 
147PSSS150), where the proline and serine were critical for binding (Sheng et al., 2006). 
This allowed for the identification of a consensus-binding motif, P/AxxS, for USP7-NTD 
substrates. Following the identification of the P/AxxS consensus motif, several other 
interacting partners of the USP7-NTD were discovered such as HdmX (Sarkari et al., 
2010), UbE2E1 (Sarkari et al., 2013), MCM-BP (Jagannathan et al., 2014) and CHFR 
(Luthra et al., unpublished), all of which contain this consensus sequence. Figure 1.6 
shows the USP7-NTD substrates and their P/AxxS consensus sequence.  
A 164DWGF167 motif in the USP7-NTD was shown to be essential for binding to 
substrates containing the P/AxxS motif (Sheng et al 2006). USP7-NTD Trp165 has a 
major role and USP7-NTD Asp164 has a minor role in binding to substrates (Sheng 
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et al., 2006). This was confirmed when substrate binding was abolished upon mutation of 
Trp165 and reduced two-fold upon mutation of Asp164 (Sheng et al., 2006).  
  
 
Figure 1.6: USP7 substrates contain a P/AxxS motif. Several USP7 substrates that 
bind to the USP7-NTD contain a P/AxxS binding motif that is required for binding to the 
USP7 protein.  
 
 
1.6.4 USP7 Interacts with the Class III Ubiquitin-conjugating Enzyme 
UbE2E1  
 
It has recently been demonstrated that the class III ubiquitin-conjugating enzyme 
UbE2E1 binds to the USP7-NTD. Analysis of the UbE2E1 protein sequence revealed that 
its N-terminal extension contains the USP7 binding motif P/AxxS (Sarkari et al., 2013). 
Using a GST-pull down assay, Sarkari et al. (2013) showed that UbE2E1 interacts with 
USP7 via the 8ASTS11 motif in its N-terminal extension and the 164DWGF167 motif in the 
USP7-NTD. The interaction between UbE2E1 and USP7 was further validated in vivo 
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using a coimmunoprecipitation assay (Sarkari et al., 2013).  
The detailed molecular mechanism of interaction between USP7 and UbE2E1 was 
determined through x-ray crystallography. Sarkari et al. (2013) determined the structure 
of the USP7-NTD in complex with a UbE2E1 peptide containing the P/AxxS binding 
motif. The structure confirmed that the interaction occurs between 8ASTS11 in UbE2E1 
and 164DWGF167 in the USP7-NTD. Ser11 of UbE2E1 made the most contacts with the 
USP7-NTD, forming two hydrogen bonds with Asp164 of USP7 (Sarkari et al., 2013).  
Sarkari et al. (2013) also demonstrated the effect of the USP7:UbE2E1 
interaction. An in vitro ubiquitination assay revealed that in the presence of USP7, 
UbE2E1 mediated ubiquitination was reduced. The decreased level of ubiquitination was 
dependent on the interaction between the USP7-NTD and the UbE2E1 N-terminal 
extension. Furthermore, USP7 reduced the levels of polyubiquitinated UbE2E1, 
suggesting that UbE2E1 is a deubiquitination substrate of USP7 (Sarkari et al., 2013). 
Consistent with these results was the ability of USP7 to regulate the cellular stability of 
UbE2E1 (Sarkari et al., 2013).  
1.7 Preliminary Work  
 Protein sequence analysis of UbE2E2 and UbE2E3 revealed that these proteins 
contain the USP7 binding motif P/AxxS in their N-terminal extension. Preliminary 
studies showed that UbE2E2 and UbE2E3 interact with the USP7-NTD via their 
N-terminal extensions in vitro (Mohamed et al, unpublished). A GST pull down was 
performed using wild type UbE2E proteins and GST-USP7-NTD. Figure 1.7A shows that 
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GST protein alone was unable to retain the UbE2E proteins suggesting that the UbE2E 
proteins do not bind to the GST protein. However, when the GST protein was fused with 
USP7-NTD, both UbE2E proteins appeared in the elution, suggesting that the UbE2E 
proteins interact with the USP7-NTD (Figure 1.7B). The GST pull down was repeated 
using mutated UbE2E proteins, in which the N-terminal extension containing the P/AxxS 
binding motif was deleted. The N-terminal mutants were unable to bind GST-USP7, 
suggesting that the UbE2E proteins interact with USP7 via their N-terminal extension 
(Figure 1.7C).  Finally, to confirm that USP7 is interacting with the UbE2E proteins via 
the 164DWGF167 motif in its NTD, a double point mutant, USP7-NTDDW, in which Asp164 
and Trp165 were changed to alanine residues, was used. Figure 1.7D shows that the 
GST-USP7-NTDDW mutant did not bind to the UbE2E proteins. Together the results from 
Mohamed et al. (unpublished) suggest that the UbE2E proteins directly interact with the 
USP7-NTD in vitro via the P/AxxS motif in their N-terminal extension and the 
164DWGF167 motif in the USP7-NTD.  
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Figure 1.7: UbE2E2 and UbE2E3 interact with the USP7-NTD in vitro via their 
N-terminal extension. A GST pull-down was performed using GST-USP7-NTD and 
UbE2E proteins: UbE2E2 and UbE2E3.  GST-USP7-NTD was incubated with the 
UbE2E proteins and loaded on to a glutathione resin (L). The resin was washed several 
times (W) and eluted using SDS-PAGE loading dye (E). GST-pull down (A) control 
using GST protein and wild-type UbE2E proteins (B) GST-USP7-NTD and wild-type 
UbE2E proteins (C) GST-USP7-NTD and a N-terminal deletion mutant of the UbE2E 
proteins (D) GST-USP7DW and wild-type UbE2E proteins. This figure was retrieved from 
Mohamed et al., unpublished. 
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 The interaction between the UbE2E proteins and the USP7-NTD was further 
studied using an intrinsic tryptophan fluorescence assay (Mohamed et al., unpublished). 
This assay used peptides corresponding to the binding motif in each of the UbE2E 
proteins. The dissociation constant between USP7-NTD and the respective UbE2E 
peptide was obtained by monitoring the change in intrinsic tryptophan fluorescence of 
USP7-NTD as increasing concentrations of UbE2E peptide was added. The dissociation 
constants revealed that each of the UbE2E proteins has a high binding affinity for 
USP7-NTD (Figure 1.8).  
 
Figure 1.8: UbE2E proteins have a high binding affinity for USP7-NTD. Intrinsic 
tryptophan fluorescence assay showing binding affinity between UbE2E peptides and 
USP7-NTD. The table shows the dissociation constants between USP7-NTD and UbE2E 
peptides that were measured by the assay. The figure was retrieved from 
Mohamed et al. (unpublished).  
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1.8 Summary and Rationale  
 Previous studies have revealed that the USP7-NTD recognizes a P/AxxS motif in 
its substrates. A sequence analysis of the class III ubiquitin conjugating enzymes 
(UbE2E1, UbE2E2 and UbE2E3) revealed that these enzymes contain a conserved 
P/AxxS motif in their N-terminal extensions. Sarkari et al. (2013) demonstrated that 
UbE2E1 interacts with the USP7-NTD both in vivo and in vitro. A crystal structure of the 
USP7-NTD in complex with a UbE2E1 peptide revealed that the interaction occurs 
between the 8ASTS11 motif in the UbE2E1 N-terminal extension and the 164DWGF167 
motif in the USP7-NTD. Through this interaction USP7 is able to deubiquitinate and 
salvage UbE2E1 from proteasomal degradation, thereby stabilizing cellular levels of 
UbE2E1 (Sarkari et al., 2013).  
 A preliminary study revealed that UbE2E2 and UbE2E3 directly interact with the 
USP7-NTD in vitro via their N-terminal extension. The objective of this project is 
threefold. First, we want to determine whether UbE2E2 and UbE2E3 interact with USP7 
in vivo. Second, we want to determine the details of molecular interaction between 
UbE2E2 and the USP7-NTD, as well as, UbE2E3 and the USP7-NTD. Finally, we want 
to determine what effect the interaction has.  
 It is hypothesized that USP7 will interact with both UbE2E2 and UbE2E3 in vivo. 
We expect that the PSTS motif in the N-terminal extension of these proteins is involved 
in the interaction with the USP7-NTD and that the interaction is similar to what has been 
previously observed with other USP7-NTD substrates such as UbE2E1, p53 and Mdm2. 
Finally, we hypothesize that like UbE2E1, the interaction between UbE2E2 and 
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USP7 as well as UbE2E3 and USP7 leads to the stabilization of these proteins through 
USP7-mediated deubiquitination.  
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CHAPTER 2: MATERIALS AND METHODS  
2.1 PCR Primer Synthesis  
 PCR primers for ube2e2 and ube2e3 were synthesized by Integrated DNA 
Technologies Inc. (IDT) (Toronto, Canada). The forward primers contained an XhoI 
restriction site sequence and an additional two nucleotides that were homologous to the 
pCMV3F-C cloning vector. The reverse primers contained the KpnI restriction site 
sequence. The sequence of the forward and reverse primers for Ube2e2 and Ube2e3 can 
be found in Table 2.1.  
 
Table 2.1: PCR primer sequences for Ube2e2 and Ube2e3. The forward and reverse 
primers contain an XhoI and KpnI restriction site sequence, respectively.  
 
Ube2e2 Forward  5’-GCACTCGAGCTATGTCCACTGAGGCACAAAGAG-3’ 
Reverse  5’-CAGGGTACCTGTGGCGTACCGCTTGGTCCA-3’ 
Ube2e3 Forward 5’-GCACTCGAGCTATGTCCAGTGATAGGCAAAGGTCCG-3’ 
Reverse  5’-CAGGGTACCTGTTGCGTATCTCTTGGTCCACTG-3’ 
*Blue – leader sequence, *Red – restriction site, *Green – bases homologous to vector, 
*Black – hybridization sequence  
 
2.2 Isolation and purification of ube2e2 and ube2e3 cDNA  
 Ube2e2 and ube2e3 cDNA was isolated from a pET28 vector by PCR. A PCR 
reaction mixture was prepared on ice. Each reaction contained 1X pfu buffer (200mM 
Tris-HCl pH 8.8, 100mM (NH4)2SO4, 2mM MgSO4 ), 400µM dNTP mix (Fermentas Life 
Sciences), 1µ1 of plasmid DNA, 1µM of forward primer (IDT), 1µM of reverse primer 
(IDT) and 0.1µl of pfu DNA polymerase (purified from E. coli), in a total volume of  
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50µl.  The PCR reaction was performed using Thermo Scientific® Px2 Thermal Cycler, 
the conditions of the PCR cycle are outlined in Table 2.2. The resulting amplified cDNA 
was resolved on a 1% agarose gel. The bands corresponding to the cDNA fragment of 
interest were excised from the gel, weighed and purified using GE Healthcare illustra™ 
GFX™ PCR DNA and Gel Band Purification Kit as outlined by the manufacturer. The 
DNA was eluted in 30µl of warm ddH2O. The concentration of the purified cDNA was 
measured using Thermo Scientific® NanoDrop™ 2000. 
   
Table 2.2: PCR cycle conditions.  
STAGE 1: Denaturation (1 cycle) 95°C, 3 minutes  
STAGE 2: Annealing (30 cycles) Step 1: 95°C, 45 seconds 
Step 2: Annealing Temperature, 1 minute 
Step 3: 72°C, 5 minutes 
STAGE 3: Extension (1 cycle) 72°C, 20 minutes 
 
2.3 Isolation and purification of pCMV3F-C plasmid  
 The pCMV3F-C plasmid was transformed into chemically competent DH5% E. 
coli cells via heat shock transformation. The plasmid was isolated and purified using 
QIAGEN® QIAprep™ Spin Miniprep Kit as outlined by the manufacturer. The DNA 
was eluted using 50µl of warm ddH2O. The concentration of the plasmid was measured 
using Thermo Scientific® NanoDrop™ 2000.    
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2.4 Molecular Cloning of ube2e2 and ube2e3 in to pCMV3F-C 
2.4.1 Restriction Digestion  
 The purified ube2e inserts and pCMV3F-C plasmid were subjected to restriction 
digestion by XhoI and KpnI, which would cleave the DNA at the sites indicated in Figure 
2.1. Each reaction contained 1µg of DNA, 1X NEBuffer 1 (New England Biolabs Inc.), 
10ng of BSA, and 1µl of Xho1 (New England Biolabs Inc.) in a final volume of 50µl. The 
reaction was allowed to proceed at 37°C for 1 hour. Following digestion XhoI was heat 
inactivated at 65°C for 20 minutes. KpnI was then added to the reaction and the reaction 
volume was adjusted to 60µl. The reaction was incubated at 37°C for 10 minutes. A 
reaction cleanup was performed following digestion using GE Healthcare illustra™ 
GFX™ PCR DNA and Gel Band Purification Kit. To verify digestion, the digested 
inserts and plasmid were resolved on a 1% agarose gel and observed by ethidium 
bromide staining.  
 
 
Figure 2.1: Restriction sites of XhoI and KpnI. After digestion XhoI creates a 5’ 
overhang and KpnI creates a 3’ overhang.  
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2.4.2 Ligation and Transformation  
 Digested ube2e2 and ube2e3 inserts were ligated into the digested pCMV3F-C 
plasmid in a 1:3 plasmid to insert molar ratio. The reaction contained 0.1µg plasmid, 
0.3µg insert, 1X T4 ligase Buffer (New England Biolabs Inc.) and 400 units of T4 DNA 
Ligase (400 000 U/ml, New England Biolabs Inc.), in a volume of 10µl. The reaction was 
allowed to proceed overnight at 16°C.  The resulting recombinant plasmids were 
transformed into chemically competent DH5% E. coli cells via heat shock transformation. 
The transformed cells were plated on to LB agar plates containing 50ng/ml kanaMycin 
used for selection and incubated overnight at 37!C. Of the resulting colonies, six were 
selected and cultured overnight at 37!C in 5ml of LB broth containing 50ng/ml 
kanaMycin.  Plasmid DNA was isolated and purified from the resulting culture using 
QIAGEN® QIAprep™ Spin Miniprep Kit.  The plasmid DNA was eluted using 50µl of 
warm ddH2O. In order to verify successful ligation, the purified recombinant plasmids 
were digested with XhoI and KpnI as previously described and were resolved on a 1% 
agarose gel for analysis by ethidium bromide staining.  
2.5 Sequencing and Sequence Analysis 
 Recombinant plasmids were sent to the sequencing facility at York University, 
Department of Biology. The sequences obtained were analyzed using NCBI Blast, 
ClustalW and ExPASy Translate Tool.   
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2.6 Cell Culture  
 The cell lines used in this project were Human Embryonic Kidney (HEK) 293T, 
Human Osteosarcoma (U2OS), Human Colon Carcinoma (HCT116) and HCT116 USP7 
-/-, which were kindly provided by Dr. Bert Vogelstein (John Hopkins). Cells were kept 
at 37°C and 5% CO2 in a Thermo Scientific® Forma™ Steri-Cycle™ CO2 Incubator. 
U2OS and HCT116 cells were grown in McCoy’s media (Wisent Bio Products) 
supplemented with 10% FBS and HEK293T cells were grown in DMEM media (Thermo 
Scientific) supplemented with 10% FBS. The cells were passaged after 48 hours.  
2.7 Transfection  
 Cells were plated 24 hours prior to transfection in a 10 cm plate, in order to reach 
a confluency of 80% at the time of transfection.  Thirty minutes prior to transfection, 
10ml fresh growth media supplemented with 10% FBS was added to the cells.  
Transfection was carried out using PolyJet™ In Vitro DNA Transfection Reagent 
(SignaGen® Laboratories) using a 3:1 ratio of PolyJet™ (µl) to DNA (µg). In a 
microfuge tube, 10µg of plasmid DNA was mixed with 400µl of serum-free McCoy’s 
media. In a separate microfuge tube, 30µl of PolyJet™ was mixed with 400µl of 
serum-free McCoy’s media and immediately added to the DNA mixture. The 
DNA/PolyJet™ mixture was incubated for 15 minutes at room temperature and was 
subsequently added drop wise to the cell plate. The DNA/PolyJet™ containing media 
was replaced 18 hours after transfection with fresh growth media supplemented with 10% 
FBS. Cells were harvested for further analysis 48 hours post-transfection.  
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2.8 Transfection Efficiency of HCT116 USP7 -/- Cells 
HCT116 USP7 -/- cells were allowed to grow in two separate 6cm dishes, each 
containing a glass coverslip, to 85% confluency. The cells were transfected with Green 
Fluorescent Protein (GFP) using either Lipofectamine® 2000 Transfection Reagent (Life 
Technologies) or PolyJet™ In Vitro DNA Transfection Reagent (SignaGen® 
Laboratories).  Forty-eight hours post-transfection, the coverslips were removed from the 
plates and the cells grown on the coverslips were washed 3X with 1X PBS. Following the 
washes the cells were fixed in 2% paraformaldehyde in 1X PBS. The cells were then 
permeabilized in 0.5% Triton X-100 in 1X PBS. Cells were washed twice with PBST 
(PBS with 0.1% Tween 20). The nucleus was stained with Prolong® Gold Antifade 
Reagent with DAPI (Life Technologies) and mounted on glass microscope slides. Images 
were obtained using a Zeiss LSM 700 confocal microscope. The transfection efficiency 
was calculated by dividing the amount of GFP-positive cells by the amount of DAPI 
stained cells in the field of view.  
2.9 Western Blotting  
 Whole cell extracts were resolved on 12% SDS-PAGE. The gel was 
electrophoresed at 70V for 30 minutes or until the bands travelled through the stacking 
gel and at 195V for the next 40 minutes. The proteins on the gel were transferred to a 
polyvinylidene difluoride (PVDF) membrane at 30V using an electrophoretic transfer cell 
(Biorad) overnight at 4°C. The resulting membrane was incubated in blocking buffer (5% 
nonfat milk in 1X PBS) for one hour at room temperature. The membrane was rinsed 3X 
with 1X PBS-T (recipe) and incubated with primary antibody diluted in 
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blocking buffer for one hour at room temperature. The membrane was washed 3X for 5 
minutes with PBS-T, rinsing in between each wash. Following the washes, the membrane 
was incubated with horseradish peroxidase-conjugated anti-mouse antibody (1:20000 
dilution in blocking buffer) or anti-rabbit antibody (1:10000 dilution in blocking buffer) 
for 30 minutes. The membrane was washed 3X for 15 minutes in 1X PBS-T, rinsing in 
between each wash.  The membrane was then incubated in ECL solution (GE Healthcare) 
for 1 minute in dark conditions, exposed to film and developed for analysis. Western 
blots were quantified using ImageJ software.  
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2.10 Immunoprecipitations  
 Human Embryonic Kidney (HEK) 293T cells were co-transfected with 
Myc-tagged USP7 and Flag-tagged UbE2Es. Forty-eight hours post-transfection the cells 
were harvested and lysed using lysis buffer (50mM Tris pH 8.0, 150mM NaCl, 0.5% NP-
40, 1X protease inhibitor cocktail and 1X protease inhibitor tablet (Roche)). The cells 
were lysed for 15 minutes at 4ºC while rotating. The cells were then sonicated using 
Branson Digital Sonifier" at 10% amplitude for 2 pulses (1 second on, one second off). 
The lysed cell were centrifuged at 17 000 xg for 10 minutes at 4ºC. The concentration of 
the cell lysate was quantified using a Bradford protein assay (Bioshop).  Cells used for 
the control experiment were co-transfected with an empty vector and Myc-tagged USP7.  
 
2.10.1 Immunoprecipitation of Flag-UBE2Es 
 Forty microliters of anti-Flag M2 affinity gel beads (Sigma, A2220) were 
pre-washed three times with 0.5ml of 1X PBS. One milligram of total cell lysate was 
incubated with the pre-washed beads, overnight at 4°C. The immunoprecipitated complex 
was washed four times with lysis buffer (50mM Tris pH 8.0, 150mM NaCl, 0.5% NP-40) 
and was eluted by boiling in 5X SDS loading dye. The elution was resolved on 12% 
SDS-PAGE followed by immunoblotting with antibodies against Myc-tag (Abcam, 
ab9106) and Flag-tag (Sigma, F3165). Cells co-transfected with empty pCMV3F-C 
vector and Myc-tagged USP7 were used as a negative control.  
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2.10.2 Immunoprecipitation of Myc-USP7 
 Cell lysate obtained from a single batch of cells was divided into two microfuge 
tubes, each containing one milligram of total cell lysate. The cell lysate was pre-cleared 
with Protein A/G PLUS Agarose (Santa Cruz, sc-2003) for 30 minutes at 4°C. The 
pre-cleared lysate was incubated with 2µg of Myc tag antibody (Abcam, ab9106) or 2µg 
of normal rabbit IgG (Santa Cruz, sc-2027) overnight at 4°C.  Following incubation, 30µl 
of Protein A/G PLUS Agarose (Santa Cruz, sc-2003) was added to the lysates and 
incubated for 1 hour at 4°C.  The immunoprecipitated complex was washed 4X with lysis 
buffer (50mM Tris pH 8.0, 150mM NaCl, 0.5% NP-40) and was eluted by boiling in 5X 
SDS loading dye. The elution was resolved on 12% SDS-PAGE followed by 
immunoblotting with antibodies against Myc-tag and Flag-tag (Sigma, F3165).  
2.11 Synthesis of UbE2E2 and UbE2E3 Peptides 
 The UbE2E2 and UbE2E3 peptides used for crystallization were synthesized by 
CanPeptide Inc. (Montreal, Canada). In order to mimic natural peptides, the peptides 
were acetylated at the N-terminal end and amidated at the C-terminal end. Peptides were 
dissolved in crystallization buffer prior to use.   
2.12 Crystallization of USP7-NTD:UbE2E2 and USP7-NTD:UbE2E3 
2.12.1 Purification of USP7-NTD 
 USP7-NTD was purified by Niharika Luthra, York University. USP7-NTD was 
purified using Ni2+ Affinity Chromatography and eluted in a buffer containing 100mM  
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Hepes pH 7.5, 500mM NaCl, 10% glycerol, 250mM Imidazole and 0.5mM TCEP. 
Thrombin was used to remove the 6X His-tag from the purified USP7-NTD. The 
His-cleaved USP7-NTD was subjected to size exclusion chromatography in order to 
remove impurities and exchange the buffer to 20mM Hepes pH 7.5, 500mM NaCl. The 
cleaved protein was used for co-crystal trials.  
 
2.12.2 Co-Crystallization of USP7-NTD with UbE2E Peptides 
 Purified USP7-NTD was concentrated to 100mg/ml and mixed with 5-fold molar 
excess of peptide for either UbE2E2 (9DDSPSTSGGS18) or UbE2E3 (10DESPSTSSGS19). 
In order to allow complex formation, the mixture was incubated overnight at 4ºC. 
Following incubation, co-crystal trials were set up for the USP7-NTD:UbE2EPSTS 
complex using USP7-NTD:HdmX as microseeds.   1µl of protein complex was mixed 
with 0.25µl of USP7-NTD:HdmX as microseed and 0.75µl crystallization buffer (30% 
PEG 4000, 0.1M Tris pH 8.5 and 0.2M Lithium Sulfate). The resulting 2µl mixture was 
sealed in a chamber using the hanging drop method. The sealed chamber was incubated 
at 4ºC in dark conditions.  
 
2.12.3 Data Collection and Structure Determination  
The USP7-NTD:UbE2E2 PSTS and USP7-NTD:UbE2E3 PSTS crystals were flash 
frozen. X-ray data from the frozen crystals was collected at 100K on a Rigaku 
MicroMax007 rotating anode diffractometer with a 944+ CCD detector. HKL-2000 
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software was used to integrate and scale the data. The molecular replacement component 
in CNS (version 1.3) was used to determine the structure using USP7-NTD (PDB ID 
1YY6) without peptide as the search model. CNS 1.3 was also used for picking water 
molecules and for refinement of torsion angles and B-factors. The program Coot was 
used for electron density visualization, model building and model rebuilding (after 
inspecting 2Fo-Fc and Fo-Fc maps). Figures were created using PyMol.    
2.13 UbE2E2 Turnover Assay in HCT116 Cells  
 HCT116 WT and HCT116 USP7 -/- cells were grown in 6cm dishes to 75% 
confluency. The cells were treated with 50µg/ml of cycloheximide (Sigma, C4859) 
diluted in complete media. The cells were harvested 0, 2, 4, 8, 24 and 48 hours 
post-treatment. Cells were lysed with lysis buffer (50mM Tris pH 8.0, 150mM NaCl, 
0.5% NP-40, 1X protease inhibitor cocktail and 1X protease inhibitor tablet  (Roche)). 
Lysis was allowed to proceed for 15 minutes at 4ºC, while rocking followed by 
sonication using Branson Digital Sonifier" at 10% amplitude and 2 pulses (1 second on, 
1 second off). The cell lysate was then centrifuged at 17 000 xg at 4ºC. Fifty micrograms 
of total cell lysate was resolved on 12% SDS-PAGE and immunoblotted with antibodies 
against USP7 (Bethyl, A300-033A), UbE2E2 (Bethyl, A303-485A) and GAPDH (Santa 
Cruz, 0411). 
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2.14 USP7 Rescue Assay in HCT116 USP7 -/- Cells  
 HCT116 USP7 -/- cells were grown in 6cm plates to 75% confluency. The cells 
were transfected with empty vector, Myc-USP7-WT, Myc-USP7-C223S and 
Myc-USP7-DW (USP7 plasmids provided by Rahima Khutan, York University). The 
cells were harvested 48 hours post-transfection. Harvested cells were lysed with lysis 
buffer (50mM Tris pH 8.0, 150mM NaCl, 0.5% NP-40, 1X protease inhibitor cocktail 
and 1X protease inhibitor tablet (Roche)).  Lysis was allowed to proceed for 15 minutes 
at 4ºC, while rocking followed by sonication using Branson Digital Sonifier" at 10% 
amplitude and 2 pulses (1 second on, 1 second off). The cell lysate was then centrifuged 
at 17 000 xg at 4ºC. Fifty micrograms of total cell lysate was resolved on 12 % 
SDS-PAGE and immunoblotted with antibodies against USP7 (Bethyl, A300-033A), 
UbE2E2 (Bethyl, A303-485A) and GAPDH (Santa Cruz, 0411). 
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CHAPTER 3: RESULTS  
3.1 USP7-NTD Interacts with UbE2E2 and UbE2E3 In Vivo 
 A previous study revealed that UbE2E2 and UbE2E3 interact with the 
USP7-NTD in vitro, via their N-terminal extension (Mohamed et al., unpublished).  To 
determine whether these proteins interact in vivo, a co-immunoprecipitation assay was 
performed. HEK293T cells were co-transfected with Myc-tagged USP7 and Flag-tagged 
UbE2E2. The cells were subjected to co-immunoprecipitation using an antibody targeted 
against the Myc-tag. An IgG antibody was used as a negative control to ensure that the 
interacting protein, in this case Flag-UbE2E2, is binding to myc-USP7 and not the IgG 
antibody. The resulting immunoprecipitated complex was observed using an immunoblot. 
Figure 3.1A shows that Flag-UbE2E2 was detected in the immunoprecipitated complex 
of Myc-USP7 but not IgG alone.  
To further validate these results, we performed the reciprocal of this experiment, 
where the co-transfected cells were subjected to co-immunoprecipitation using an 
anti-Flag antibody. Cells co-transfected with an empty pMCV3F-C vector were used as a 
negative control. Myc-USP7 was observed in the immunoprecipitated complex of 
Flag-UbE2E2 but not in the immunoprecipitated complex of cells co-transfected with an 
empty vector and Myc-USP7 (Figure 3.1B).  
The same sets of experiments were repeated for cells co-transfected with 
Myc-tagged USP7 and Flag-tagged UbE2E3. Flag-UbE2E3 was observed in the 
immunoprecipitated complex of Myc-USP7 but not IgG alone (Figure 3.2A). 
Furthermore, Myc-USP7 was observed in the immunoprecipitated complex of 
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Flag-UbE2E3 and not in cells transfected with empty vector (Figure 3.2B). Together, 
these results suggest that USP7 interacts with UbE2E2 and UbE2E3 in vivo.  
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Figure 3.1: USP7 interacts with UbE2E2 in vivo.  (A) 293T cells were co-transfected 
with Myc-USP7 and Flag-UbE2E2. Twenty-four hours post transfection whole cell 
extracts were subjected to immunoprecipitation using anti-Myc and rabbit IgG 
antibodies. The immunoprecipitated complex was immunoblotted using anti-Flag and 
anti-Myc antibodies. The input for both IP:Myc and IP:IgG came from the same cell 
extract. Thirty micrograms of whole cell extract was used as input. (B) 293T cells were 
co-transfected with Myc-USP7 and Flag-UbE2E2. For control purposes 293T cells were 
transfected with empty pCMV3F-C vector. Twenty-four hours post-transfection whole 
cell extracts were subjected to immunoprecipitation using anti-Flag M2 affinity gel. The 
immunoprecipitated complex was immunoblotted using anti-Myc and anti-Flag 
antibodies. Thirty micrograms of whole cell extract was used as input.  
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Figure 3.2: USP7 interacts with UbE2E3 in vivo.  (A) 293T cells were co-transfected 
with Myc-USP7 and Flag-UbE2E3. Twenty-four hours post transfection whole cell 
extracts were subjected to immunoprecipitation using anti-Myc and rabbit IgG 
antibodies. The immunoprecipitated complex was immunoblotted using anti-Flag and 
anti-Myc antibodies. The input for both IP:Myc and IP:IgG came from the same cell 
extract. Thirty micrograms of whole cell extract was used as input. (B) 293T cells were 
co-transfected with Myc-USP7 and Flag-UbE2E3. For control purposes 293T cells were 
transfected with empty pCMV3F-C vector. Twenty-four hours post-transfection whole 
cell extracts were subjected to immunoprecipitation using anti-Flag M2 affinity gel. The 
immunoprecipitated complex was immunoblotted using anti-Myc and anti-Flag 
antibodies. Thirty micrograms of whole cell extract was used as input.  
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3.2 Molecular Analysis of the Interaction Between USP7:UbE2E2 and 
USP7:UbE2E3 
3.2.1 Crystallization and Structure Determination of USP7:UbE2E2 and 
USP7:UbE2E3 
 
  In order to gain insight on the molecular basis of interaction between 
USP7-NTD and UbE2E2, as well as USP7-NTD and UbE2E3, we synthesized peptides 
corresponding to the interaction motif in the UbE2E2 (9DDSPSTSGGS18) and UbE2E3 
(10DESPSTSSGS19) N-terminal extensions. The peptides were co-crystallized with the 
USP7-NTD, which was purified using Ni2+ affinity chromatography. The crystals grew at 
4ºC in dark conditions after one week in a buffer containing 30% PEG 4000, 0.1M Tris 
pH 8.5 and 0.2M lithium sulfate.  The protein complexes formed between 
USP7-NTD:UbE2E212PSTS15 (USP7:UbE2E2PSTS) and USP7-NTD:UbE2E313PSTS16 
(USP7:UbE2E3PSTS) formed crystals that are rod-shaped. Figure 3.3 shows the rod-
shaped crystals formed by the USP7:UbE2E3PSTS complex. The crystals were frozen and 
exposed to X-rays, producing a unique diffraction pattern. Figure 3.4 shows the 
diffraction pattern produced for the USP7:UbE2E3PSTS complex. Figure 3.4A shows 
reflections at lower resolutions; reflections are clearly observed until the 2.99Å resolution 
shell. A magnified image of the higher resolution shells shows reflections in the 2.11Å 
resolution shell (Figure 3.4B).  
 The crystal structures of USP7-NTD:UbE2E2PSTS and USP7-NTD:UbE2E3PSTS 
were determined using molecular replacement to a resolution of 1.75Å and 2.00Å, 
respectively (Table 3.1).  The structure of USP7-NTD:UbE2E2PSTS was refined to an 
Rwork of 0.198 and an Rfree of 0.215 with 126 water molecules (Table 3.1). The 
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structure for USP7:UbE2E3PSTS was refined to an Rwork of 0.207 and an Rfree of 0.240 
with 175 water molecules (Table 3.1). The Ramachandran Plot for both 
USP7:UbE2E2PSTS and USP7:UbE2E3PSTS indicates that 95.6% of the residues were in 
their most favored spot.    
 
 
Figure 3.3: UbE2E313PSTS16 co-crystalized with USP7-NTD forming long, rod-
shaped crystals. 100 mg/ml of purified USP7-NTD was incubated with 5-fold molar 
excess of UbE2E3 peptide 10DESPSTSSGS19, overnight at 4°C. Co-crystal trials were set 
up using USP7-NTD:HdmX as a microseed and a crystallization buffer containing 30% 
PEG 4000, 0.1M Tris pH 8.5 and 0.2M Lithium Sulfate. Crystals grew in dark conditions 
at 4°C over a one week period. The crystals obtained were long and rod-shaped. 
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Figure 3.4: X-ray diffraction pattern from a USP7:UbE2E3PSTS co-crystal. X-ray 
data was collected at 100K on a Rigaku MicroMax007 rotating anode diffractometer with 
a 944+ CCD detector using a frozen protein crystal.  When an X-ray beam strikes the 
protein crystal, it produces a pattern of spots called reflections on a detector. The relative 
intensity and position of the reflections can be used to determine the arrangement of 
molecules within the crystal. (A) An image of the resulting diffraction pattern showing 
reflections in all resolution shells. (B) Magnified image showing reflections in higher 
resolution shells. Some reflections are circled red. 
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Table 3.1: X-ray data collection and refinement parameters for USP7:UbE2E2PSTS 
and USP7:UbE2E3PSTS 
X-Ray Data UbE2E2 
(9DDSPSTSGGS18) 
UbE2E3  
(10DESPSTSSGS19) 
Space Group P41 P41 
Resolution (Å) 50.0 – 1.75 50.0 – 2.00 
Unit Cell Axis (Å3)  69.9 x 69.9 x 45.7 70.0 x 70.0 x 46.0 
Molecules/AU 1 1 
Total Observations (#) 132 400 108 466 
Unique Reflections (#) 21738 14 277 
Intensity (I / &<I>) 20.1 (2.1) 12.8 (2.8) 
Completeness (%) 96.8 (74.7) 93.6 (88.8) 
aRsym 0.063 (0.570) 0.083 (0.337) 
Refinement  
Rwork 0.198 0.207 
Rfree 0.215 0.240 
Protein Atoms (#) 1160 1362 
Water Molecules (#) 126 175 
rmsd bonds (Å) 0.005 0.006 
rmsd angles (°) 1.4 1.4 
rmsd dihedrals (°) 25.3 25.5 
rmsd improper (°) 0.87 0.83 
Thermal factors (Å2) 17.0 19.6 
Ramachandran Plot  
Most Favoured  0.956 0.956 
Additionally allowed  0.037 0.044 
 
Numbers in brackets refer to the highest resolution shell, 1.78 Å to 1.75 Å for the 
USP7:UbE2E2PSTS data and 2.08 to 2.00 Å for the USP7:UbE2E3PSTS data. aRsym = # |I-
<I>| /#I where I is the observed intensity and <I> is the average intensity from multiple 
observations of symmetry-related reflections. 
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3.2.2 UbE2E2 and UbE2E3 Bind the !7-strand of the USP7-NTD 
The molecular structure of USP7-NTD and UbE2E212PSTS15 is displayed in 
Figure 3.5A with the USP7-NTD displayed in violet and the UbE2E212PSTS15 peptide 
displayed in green. In this model, the USP7-NTD begins at residue 63 instead of 54 
because the initial residues are too disordered to assign their atomic structure. 
Furthermore, the UbE2E2 peptide, 9DDSPSTSGGS18, has been modeled from residues 
12-15. The structure of the USP7-NTD has been previously described as an anti-parallel 
!-sandwich comprising of eight anti-parallel !-strands. Figure 3.5A shows that the 
UbE2E2 peptide binds the !7 strand of the USP7-NTD. A side view of the protein 
complex shows that the UbE2E2 peptide hugs the !7 strand and makes contacts with two 
additional ! strands along its length (Figure 3.5B). Figures 3.5C and 3.5D depict a 
surface diagram and an electrostatic diagram, respectively, of USP7-NTD bound to the 
UbE2E2 peptide.  
The molecular structure of USP7-NTD and UbE2E313PSTS16 is displayed in 
Figure 3.6A with USP7-NTD displayed in blue and the UbE2E313PSTS16 peptide 
displayed in yellow. Like in the USP7-NTD:UbE2E212PSTS15 structure, the USP7-NTD 
is modeled from residue 63 instead of 54. The UbE2E3 peptide, 10DESPSTSSGS19, is 
modeled from residues 11-16. The UbE2E3 peptide binds the !7 strand of the USP7-
NTD (Figure 3.6A). Like the UbE2E2 peptide, the UbE2E3 peptide hugs the !7 and 
contacts two additional ! strands along its length (Figure 3.6B). Figure 3.6C and Figure 
3.6D show a surface and electrostatic diagram, respectively, of the USP7-NTD bound to 
the UbE2E3 peptide.  
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Figure 3.5: The crystal structure of USP7-NTD binding to UbE2E212PSTS15 reveals 
that UbE2E2 binds USP7 at !-strand !7. (A) Cartoon representation of USP7-NTD 
(violet) binding to the UbE2E212PSTS15 peptide (green). The structure reveals that 
UbE2E2 binds the !7 strand of USP7.  (B) A side representation of the UbE2E2 peptide 
(green) binding the USP7-NTD (violet) showing that the peptide hugs the !7 strand of 
USP7. (C) A surface and (D) electrostatic representation of UbE2E212PSTS15 binding to 
USP7-NTD.  
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Figure 3.6: The crystal structure of USP7-NTD binding to UbE2E313PSTS16 reveals 
that UbE2E3 binds USP7 at !-strand !7. (A) Cartoon representation of USP7-NTD 
(blue) binding to the UbE2E313PSTS16 peptide (yellow). The structure reveals that 
UbE2E3 binds the !7 strand of USP7.  (B) A side representation of the UbE2E3 peptide 
(yellow) binding the USP7-NTD (blue) showing that the peptide hugs the !7 strand of 
USP7. (C) A surface and (D) electrostatic representation of UbE2E313PSTS16 binding to 
USP7-NTD.  
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3.2.3 UbE2E2 and UbE2E3 sit in a shallow groove on the surface of the 
USP7-NTD when binding to the !7 strand 
 
 Figure 3.7A and 3.7C depict cartoon and surface diagrams, respectively, of the 
USP7-NTD (violet) bound to the UbE2E2 peptide (green). It is evident from these figures 
that the UbE2E2 peptide sits in a shallow groove on the surface of the USP7-NTD. When 
Figure 3.7A is rotated 45 degrees, it can be seen that the !7 strand of the USP7-NTD 
makes up part of the shallow groove (Figure 3.7B). Figure 3.7C, when rotated 45 
degrees, shows that the UbE2E2 peptide perfectly fits into the shallow groove on the 
surface of the USP7-NTD (Figure 3.7D).  
 Identical observations were made for the interaction between the USP7-NTD 
(blue) and the UbE2E3 peptide (yellow) (Figure 3.8). Figure 3.8A and Figure 3.8C show 
that the UbE2E3 peptide binds the USP7-NTD at the shallow groove. The shallow groove 
contains the !7 strand of the USP7-NTD, which binds the UbE2E3 peptide (Figure 3.8B). 
The UbE2E3 peptide sits perfectly in the shallow groove on the surface of the 
USP7-NTD (Figure 3.8D). 
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Figure 3.7: UbE2E212PSTS15 binds the shallow groove on the surface of USP7-NTD 
containing the !7 strand residues 164DWGF167. (A) A cartoon representation of the 
UbE2E212PSTS15 peptide (green) binding USP7-NTD (violet) (B) rotated 45° showing 
that the UbE2E212PSTS15 peptide binds in the shallow groove of USP7-NTD containing 
the !7 strand residues 164DWGF167. (C) Surface representation of the UbE2E212PSTS15 
peptide (green) binding USP7-NTD (violet) (D) rotated 45° showing that the 
UbE2E212PSTS15 peptide binds in the shallow groove of USP7-NTD containing the !7 
strand residues 164DWGF167. 
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Figure 3.8: UbE2E313PSTS16 binds the USP7-NTD at the shallow groove containing 
the !7 strand residues 164DWGF167. (A) A cartoon representation of the 
UbE2E313PSTS16 peptide (yellow) binding USP7-NTD (blue) (B) rotated 45° showing 
that the UbE2E313PSTS16 peptide binds in the shallow groove of USP7-NTD containing 
the !7 strand residues 164DWGF167. (C) Surface representation of the UbE2E313PSTS16 
peptide (yellow) binding USP7-NTD (blue) (D) rotated 45° showing that the 
UbE2E313PSTS16 peptide binds in the shallow groove of USP7-NTD containing the !7 
strand residues 164DWGF167. 
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3.2.4 UbE2E2 and UbE2E3 Make Several Contacts with the USP7-NTD 
The UbE2E212PSTS15 and the UbE2E313PSTS16 peptides form several 
interactions with the !7-strand of the USP7-NTD. Pro12 of UbE2E2 and Pro13 of 
UbE2E3 form Van der Waals interactions with USP7 Trp165 and Phe167 (Figure 3.9 B; 
Figure 3.10B). The side chain hydroxyl of UbE2E2 Ser13 and UbE2E3 Ser14 forms a 
water-mediated hydrogen bond with the main-chain amide of USP7 Ser168 (Figure 3.9C; 
Figure 3.10C). The main-chain amide and carbonyl groups of UbE2E2 Ser13 and 
UbE2E3 Ser14 interact with the main-chain amide and carbonyl groups of USP7 Gly166 
(Figure 3.9C; Figure 3.10C).  UbE2E2 Thr14 and UbE2E3 Thr15 do not make any 
interactions with the USP7-NTD (Figure 3.9B; Figure 3.10B). The side-chain hydroxyl of 
UbE2E2 Ser15 and UbE2E3 Ser16 forms hydrogen bonds with the main and side chain 
of USP7 Asp164 (Figure 3.9D)  
 The crystal structure of another class III ubiquitin-conjugating enzyme, UbE2E1, 
in complex with the USP7–NTD, was recently determined (Sarkari et al., 2013). UbE2E1 
has an ASTS motif in its N-terminal extension, whereas UbE2E2 and UbE2E3 have a 
PSTS motif.  The peptide for UbE2E1 and UbE2E2 are shown in Figure 3.11A and 
Figure 3.11B. An overlay of the peptides shows that all residues are completely aligned, 
indicating that they have a conserved interaction with the USP7-NTD (Figure 3.11C; 
Figure 3.12C). When the overlay is rotated 180 degrees, the difference of Pro12 in 
UbE2E2 and Ala8 in UbE2E1 can be seen. Although the residues are different, they align 
perfectly (Figure 3.11D). The same observations were made when comparing the 
UbE2E1 peptide to that UbE2E3 in Figure 3.12. 
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Figure 3.9: Molecular details of interaction between USP7-NTD and 
UbE2E212PSTS15 peptide.  (A) A 2FoFc electron density map showing that 
UbE2E212PSTS15 at 1 &. (B) Molecular details of interaction between USP7-NTD (violet) 
and UbE2E212PSTS15 (green) are shown in stick format. Important residues for 
interaction are labeled. Black dashed lines represent hydrogen bonds. (C) A closer view 
of the hydrogen bond between Ser13 in UbE2E2, a water molecule and the main chain in 
USP7-NTD (D) A closer view of the hydrogen bond between Asp164 in USP7-NTD and 
Ser15 in UbE2E2. 
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Figure 3.10: Molecular details of interaction between USP7-NTD and 
UbE2E313PSTS16 peptide.  (A) A 2FoFc electron density map showing that 
UbE2E313PSTS16 at 1 &. (B) Molecular details of interaction between USP7-NTD (blue) 
and UbE2E313PSTS16 (yellow) are shown in stick format. Important residues for 
interaction are labeled. Black dashed lines represent hydrogen bonds. (C) A closer view 
of the hydrogen bond between Ser14 in UbE2E3, a water molecule and the main chain in 
USP7-NTD (D) A closer view of the hydrogen bond between Asp164 in USP7-NTD and 
Ser16 in UbE2E3. 
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Figure 3.11: The USP7 binding motif of UbE2E212PSTS15 compared with that of 
UbE2E18ASTS11.  (A) Stick format of UbE2E212PSTS15 and (B) UbE2E18ASTS11 
peptides showing all relevant residues. (C) Overlay of UbE2E212PSTS15 peptide (yellow) 
and UbE2E18ASTS11 peptide (cyan). All residues align perfectly, showing conserved 
interactions with USP7. (D) A rotated view of the overlay showing perfect alignment of 
the all residues. The difference of proline 12 in UbE2E2 (yellow) and alanine 8 in 
UbE2E1 (cyan) can be seen. Although the residues are different they completely align.  
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Figure 3.12: The USP7 binding motif of UbE2E313PSTS16 compared with that of 
UbE2E18ASTS11.  (A) Stick format of UbE2E313PSTS16 and (B) UbE2E18ASTS11 
peptides showing all relevant residues. (C) Overlay of UbE2E313PSTS16 peptide (green) 
and UbE2E18ASTS11 peptide (cyan). All residues align completely, showing conserved 
interactions with USP7. (D) A rotated view of the overlay showing perfect alignment of 
the all residues. The difference of proline 13 in UbE2E3 (green) and alanine 8 in UbE2E1 
(cyan) can be seen. Although the residues are different they completely align. 
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3.3 USP7 Regulates Cellular Levels of UbE2E2  
 USP7 is a de-ubiquitinating enzyme and can regulate cellular levels of its 
substrate by rescuing the substrate from ubiquitin-mediated degradation. Since UbE2E2 
and UbE2E3 interact with USP7, we sought to investigate whether USP7 regulates their 
stability. Unfortunately, none of the antibodies tested were able to detect cellular levels of 
UbE2E3; therefore experiments were performed for UbE2E2 only. A protein turnover 
assay was performed using wild type human colon carcinoma (HCT116) cells and 
HCT116 USP7 -/-, in which the USP7 gene is deleted. The cells were incubated with 
50µg/ml of cycloheximide for 2, 4, 8, 24 and 48 hours. Cells were harvested at each time 
interval to observe the levels of UbE2E2 using western blot analysis. Figure 3.13A shows 
that the cellular levels of UbE2E2, prior to cycloheximide treatment, are higher in wild-
type HCT116 cells (lane 1) compared to USP7 -/- cells (lane 7).  Following 
cycloheximide treatment, UbE2E2 levels steadily decrease throughout the 48-hour time 
interval but are not completely diminished after 48-hours in wild-type cells (Figure 
3.13A). However, in USP7-/- cells, UbE2E2 levels remain constantly low after 
cycloheximide treatment and are diminished 48-hours post-treatment (Figure 3.13A). 
UbE2E2 levels post-CHX treatment were normalized against untreated cells (time point 
0) and plotted on a line graph in Figure 3.13B. The slopes in Figure 3.13B indicate that 
the levels of UbE2E2 in HCT116 cells decrease more steadily after CHX treatment 
compared to HCT116 USP7 -/- cells.  
In order to confirm that the reduced stability of UbE2E2 in HCT116 USP7-/- cells 
is due to the absence of USP7, we re- introduced USP7 into the HCT116 USP7-/- cells. 
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The transfection efficiency of the knockout cells is poor; therefore, we tested two 
transfection reagents to determine which would provide with a better transfection 
efficiency. Lipofectamine® 2000 Transfection Reagent provided for a better transfection 
efficiency (53%) than PolyJet™ In Vitro DNA Transfection Reagent (26%) (Figure 
3.14). HCT116 USP7-/- cells were transfected with wild type USP7; a USP7 catalytic 
mutant in which the active site cysteine residue was mutated to a serine; and a USP7 
binding mutant in which the residues 164DW165 were mutated to alanine residues (Figure 
3.15A, top panel). Compared to untransfected cells, cells transfected with wild type USP7 
showed an increase in UbE2E2 levels (Figure 3.15 lane 1 and 2), suggesting that the 
absence of USP7 is responsible for the decreased stability of UbE2E2 in HCT116  
USP7-/- cells. Furthermore, compared to untransfected cells, expression of USP7-CS led 
to a further decrease in UbE2E2 stability (Figure 3.15, lane 1 and 3). The results were 
similar for cells transfected with USP7-DW (Figure 3.15, lane 1 and 4). It should be 
noted that the transfection efficiency for HCT116 USP7 -/- cells was 53% (Figure 3.14). 
A higher transfection efficiency would have resulted in higher levels of UbE2E2 in the 
cell sample.  
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Figure 3.13: USP7 may regulate the cellular stability of UbE2E2. (A) HCT116 WT 
and HCT116 USP7 -/- cells were treated with 50ug/ml of cycloheximide. The cells were 
harvested 0, 2, 4, 8, 24 and 48 hours post-treatment and were analyzed by 
immunoblotting with antibodies against USP7, UbE2E2 and GAPDH. GAPDH was used 
as a loading control.  (B) The levels of UbE2E2 in the experiment from (A) were 
normalized using UbE2E2 levels at time 0 as a loading control and presented using a line 
graph. The black line and the dashed line represent the line of best fit for HCT116 and 
USP7-/- cells, respectively. The error bars indicate standard error. The experiment was 
repeated twice (n = 2). A p-value of 0.33 was obtained. The error bars indicate standard 
error. 
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Figure 3.14:  HCT116 USP7 -/- cells have low transfection efficiency. HCT116 
USP7-/- cells were transfected with GFP using either Lipofectamine® 2000 Transfection 
Reagent or PolyJet™ In Vitro DNA Transfection Reagent. The cells were stained with 
DAPI reagent and observed under 40X objective using a Zeiss LSM 700 confocal 
microscope. Transfection efficiency was calculated by dividing the number of 
GFP-positive cells by the number of DAPI stained cells in the field of view.  
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Figure 3.15:  Analysis of cellular levels of UbE2E2 after reinstatement of USP7 into 
USP7-/- cells. (A) HCT116 USP7-/- cells were transfected using Lipofectamine® 2000 
Transfection Reagent with either empty vector (EV), USP7-WT (WT), USP7-CS (CS) or 
USP7-DW (DW). The cells were lysed and blotted for UbE2E2 48 hours post-
transfection. (B) The levels of UbE2E2 were normalized using empty vector levels of 
protein as a loading control. The experiment was repeated twice (n = 2). A p-value of 
0.43 was obtained. The error bars indicate standard error. 
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CHAPTER 4: DISCUSSION  
4.1 UbE2E2 and UbE2E3 Interact with USP7 in vivo  
 
 The class III ubiquitin-conjugating enzyme UbE2E1 shares a conserved UBC 
domain with UbE2E2 and UbE2E3. In addition, like UbE2E2 and UbE2E3, UbE2E1 
harbors an N-terminal extension that contains a conserved P/AxxS motif. Sarkari et al. 
(2013) showed that USP7 was able to interact with UbE2E1 both in vivo and in vitro. 
Since UbE2E2 and UbE2E3 bear structural similarity to UbE2E1, we hypothesized that 
both proteins will interact with USP7. A preliminary study revealed that USP7 was able 
to interact with both UbE2E2 and UbE2E3 in vitro.  Therefore, using a 
co-immunoprecipitation assay we sought to confirm these results in vivo. HEK293T cells 
were co-transfected with Flag-tagged UbE2E2 and Myc-tagged USP7. Our results show 
that Flag-UbE2E2 was detected in an immunoprecipitated complex with Myc-USP7 
when cells were subjected to co-immunoprecipitation using either anti-Flag antibody or 
anti-Myc antibody (Figure 3.1), confirming that UbE2E2 interacts with USP7 in vivo.  
 A co-immunoprecipitation assay was repeated for cells co-transfected with 
Flag-UbE2E3 and Myc-USP7. Flag-UbE2E3 was detected in an immunoprecipitated 
complex with Myc-USP7 when cells were subjected to co-immunoprecipitation using 
either anti-Flag antibody or anti-Myc antibody (Figure 3.2), confirming that UbE2E3 also 
interacts with USP7 in vivo.  
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4.2 UbE2E2 and UbE2E3 bind the USP7-NTD at the shallow groove containing the 
!7-strand 
 
 In order to determine the mode of interaction between UbE2E2 and USP7 as well 
as UbE2E3 and USP7 we determined the tertiary structure of the peptide:protein complex 
using x-ray crystallography. The crystal structures of USP7:UbE2E2PSTS and 
USP7:UbE2E3PSTS were determined using molecular replacement to a resolution of 
1.75Å and 2.00Å, respectively (Table 3.1). These high resolutions allowed us to model 
the hydrogen-bonding and surrounding water molecule networks along with the 
protein:peptide structure. The Rwork and Rfree values are 0.198 and 0.215 for UbE2E2 and 
0.207 and 0.240 E2E3. They deviated by 2% for USP7:UbE2E2PSTS and 4% for 
USP7:UbE2E3PSTS indicating that the refined crystallographic structure is in agreement 
with the observed x-ray diffraction data. Furthermore, the Ramachandran Plot for both 
USP7:UbE2E2PSTS and USP7:UbE2E3PSTS indicates that 95.6% of the residues were in 
their most favored regions, further validating the accuracy of the determined crystal 
structures.  
 The crystal structure of USP7:UbE2E2PSTS and USP7:UbE2E3PSTS revealed that 
the UbE2E peptides bind to a shallow groove on the surface of the USP7-NTD containing 
the !7-strand (Figure 3.7 and Figure 3.8).  The !7-strand of USP7 contains the binding 
motif 164DWGF167, which is essential for its interaction with substrate proteins containing 
the P/AxxS motif (Saridakis et al., 2005). Furthermore, preliminary studies revealed that 
a mutated USP7 in which Asp164 and Trp165 were changed to alanine residues failed to 
bind UbE2E2 and UbE2E3 in a GST-pull down (Mohamed et al., unpublished). 
 63 
Together these results confirm that the interaction between UbE2E2 and USP7, as well as 
UbE2E3 and USP7, involves the 164DWGF167 motif. 
4.3 The PSTS motif in the N-terminal extension of UBE2E2 and UBE2E3 is involved 
the interaction with the USP7-NTD 
 
 The N-terminal extension of UbE2E2 and UbE2E3 contains a conserved PSTS 
motif. A preliminary study in our lab revealed that UbE2E2 and UbE2E3 proteins that 
lacked the N-terminal extension were unable to bind to USP7 in a GST pull down assay 
(Mohamed et al., unpublished).  Using x-ray crystallography we were able to confirm that 
the interaction between UbE2E2:USP7, as well as UbE2E3:USP7 occurs between the 
PSTS motif in the N-terminal extensions of the UbE2Es and the 164DWGF167 motif in the 
USP7-NTD !7-strand (Figure 3.9 and Figure 3.10). Specifically, Pro12 in UbE2E2 and 
Pro13 in UbE2E3 form Van der Waals interactions with USP7 Trp165 and Phe167 
(Figure 3.9 and Figure 3.10).  Ser13 in UbE2E2 and Ser13 in UbE2E3 make the most 
contacts with USP7. They form a water-mediated hydrogen bond with the main-chain 
amide of USP7 Ser168 and interact with the main-chain amide and carbonyl groups of 
USP7 Gly166 (Figure 3.9 and Figure 3.10).  The serine residues at the fourth position in 
the P/AxxS motif, Ser15 in UbE2E2 and Ser16 in UbE2E3, form hydrogen bonds with 
the main chain and side chain of USP7 Asp164 (Figure 3.9 and Figure 3.10).  This serine 
residue is most essential for binding to the USP7-NTD, as a mutation in this position in 
other USP7-NTD substrates such as UbE2E1 (Sarkari et al., 2013), p53 (Sheng et al., 
2006) and EBNA1 (Saridakis et al., 2005) abolished the interaction.  
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The interaction between the UbE2Es and the USP7-NTD is identical to other 
USP7-NTD substrates that have been previously described, such as UbE2E1, p53 and 
Mdm2. An overlap of the UbE2E2 and UbE2E3 peptides with the UbE2E1 peptide is 
displayed in Figure 3.11 and Figure 3.12, respectively. Although the first proline in 
UbE2E2 and UbE2E3 is an alanine in UbE2E1, the peptides remain completely 
superposed, confirming that the interaction of these peptides with USP7 is conserved. 
4.4 USP7 Regulates the Stability of UbE2E2 
 
 Sarkari et al. (2013) showed that USP7 was able to interact with and regulate the 
cellular levels of UbE2E1. Therefore, we hypothesized that because UbE2E2 and 
UbE2E3 bear structural resemblance to UbE2E1 and can interact with USP7, then USP7 
should also be able to regulate the levels of UbE2E2 and UbE2E3. Figure 3.13A and B 
show that UbE2E2 levels are more stable in HCT116 wild type cells when compared to 
HCT116 USP7 -/- cells, suggesting that USP7 is required for the regulation and stability 
of the UbE2E2 protein. However, a p-value of 0.33 suggests that the results obtained are 
not significant. The high p-value obtained can be due to the small sample size used, as the 
experiment was only performed twice. If the experiment is repeated several times a lower 
p-value will be obtained.  
 Although our statistical analysis leads to the conclusion that USP7 is not 
regulating the stability of UbE2E2, we sought to determine how UbE2E2 levels would be 
affected if USP7 were reintroduced into the knockout cells using ectopic expression. 
When wild-type USP7 was reintroduced into knockout cells, UbE2E2 levels 
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were increased (Figure 3.15). The increase in UbE2E2 levels is dependent on the ability 
of USP7 to bind and deubiquitinate UbE2E2. This is consistent with the fact that ectopic 
expression of a USP7 catalytic mutant (USP7-CS) or USP7 binding mutant (USP7-DW) 
further reduced the levels of UbE2E2 in USP7 knockout cells (Figure 3.15). Moreover, it 
is important to note that knockout of USP7 does not completely abolish UbE2E2 levels, 
suggesting that there are other factors in the cell that may contribute to the regulation and 
stabilization of UbE2E2.  The statistical analysis of this data set also suggests that the 
results are not statistically significant. This can also be attributed to the small sample size 
used, as the experiment was only performed twice.  
4.5 Limitations of the research  
 
 Although we were able perform a protein turnover and rescue assay for UbE2E2, 
we were unable to do the same for UbE2E3. Our study was limited in this respect 
because none of the antibodies tested were able to detect endogenous levels of UbE2E3.  
We can overcome this limitation by developing an antibody against our protein of 
interest. Plafker et al. (2008) developed and purified a rabbit polyclonal antibody specific 
for the unique N-terminal extension of UbE2E3. Their self-developed antibody proved to 
be successful in detecting endogenous levels of UbE2E3 in various cell types including 
RPE cells and HeLa cells (Plafker et al., 2008; Mirza et al., 2010).  We can continue with 
our studies for UbE2E3 once an antibody capable of detecting endogenous levels of 
UbE2E3 is developed. 
 Another limitation of our study was that our co-immunoprecipitations were 
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performed using two ectopically expressed proteins. Although the 
co-immunoprecipitations were successful in showing that UbE2E2 and UbE2E3 interact 
with USP7, our results would have been ideal if we have shown this interaction between 
the endogenous proteins. Unfortunately this could not be performed because we did not 
have an antibody to detect endogenous UbE2E3.  
 Finally, the transfection efficiency in our USP7 rescue assay was 53%. Therefore 
it is possible that the increase in UbE2E2 levels observed could have been greater if the 
transfection efficiency was higher. Sarkari et al. (2013) performed the same experiment 
to detect the levels of UbE2E1. Their transfection efficiency was also 50%, suggesting 
USP7 knockout cells may have poor transfection efficiency in general.  
4.6 Significance of the research 
 
 DUBs have been shown to regulate the levels of E3 ligases. One example is 
USP7, which interacts with and stabilizes the E3 ligase Mdm2 (Li et al., 2004; Sheng et 
al., 2006). As well, the DUB USP8 interacts with and stabilizes the RING 
finger-containing E3 ligase Nrdp1 (Wu et al., 2004). However, there has not been much 
evidence of DUBs regulating other components of the ubiquitination cascade. A recent 
study by Sarkari et al. (2013) revealed that USP7 regulates the cellular levels of the E2 
conjugating enzyme UbE2E1. The study by Sarkari et al. (2013) was the first to show 
that a DUB regulates an E2 conjugating enzyme.  
In the current study we show that USP7 interacts with and may regulate another 
E2 conjugating enzyme, UbE2E2. We also show that USP7 interacts with the E2 
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conjugating enzyme UbE2E3 and that this interaction potentially leads to its stabilization 
in the cell. In order for ubiquitination machinery to work efficiently it must target 
substrates rather than target itself for degradation. Since USP7 was shown to regulate E2 
conjugating enzymes, this study implicates USP7 as a guardian of the integrity of the 
ubiquitination machinery.  
4.7 Future Directions  
 USP7 has been implicated in several cellular processes through its ability to 
interact with various substrates. For example, the interaction between USP7 and p53 has 
implicated USP7 in tumour suppression and the interaction between USP7 and EBNA1 
has implicated USP7 in viral propagation.  Here we show that USP7 interacts with two 
different E2 conjugating enzymes called UbE2E2 and UbE2E3. Aside from their role as 
ubiquitin conjugating enzymes not much has been discovered about the function of these 
two proteins. We can uncover the cellular function of UbE2E2 and UbE2E3 by 
identifying their substrates and interacting partners through use of mass spectroscopy. 
Once their cellular function is identified USP7 could be implicated in a greater amount of 
cellular functions, further justifying the importance and multi-functional character of this 
protein. 
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CHAPTER 5: CONCLUSION 
 The objective of this project was threefold; first we wanted to determine whether 
UbE2E2 and UbE2E3 are able to interact with USP7 in vivo. Second, we wanted to 
determine the molecular details of interaction between USP7 and UbE2E2, as well as 
USP7 and UbE2E3. Finally, we wanted to study the effect of the interaction between 
USP7 and the UbE2E proteins. Using a co-immunoprecipitation assay it was established 
that USP7 interacts with both UbE2E2 and UbE2E3 in vivo. These results further validate 
the in vitro interaction observed between USP7 and UbE2E2, as well as USP7 and 
UbE2E3 in a preliminary study. Furthermore, the crystal structure of USP7:UbE2E2, as 
well as USP7:UbE2E3, demonstrated that the PSTS motif in both UbE2E2 and UbE2E3 
binds to a shallow groove on the surface of the USP7-NTD, which contains the !-strand 
residues 164DWGF167. A major contact was established between Ser15 in UbE2E2 and 
Asp164 in USP7, as well as Ser16 in UbE2E3 and Asp164 in USP7. The effect of the 
interaction between USP7 and UbE2E2 was studied using a protein turnover assay, which 
indicated that USP7 may regulate the cellular levels of UbE2E2. This study identifies an 
additional E2 conjugating enzyme that is regulated by the DUB USP7.  
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